NCT00809328

The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)

A Multicenter, Non-Randomized, Open Label Study Of Azithromycin Intravenous Followed By Oral Administration In Japanese Adult Subjects With Community Acquired Pneumonia (CAP) Requiring Initial Intravenous Therapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 102 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 16 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Azithromycin has high rates of clinical response and eradication, wide spectrum of activity, so we suppose the development of the azithromycin injectable formulation in Japan would deliver benefit to patients of community acquired pneumonia.

Conditions

• Community Acquired Pneumonia (CAP)

Interventions

Type	Name	Description
DRUG	Azithromycin	The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.

Timeline

• Start date: 2009-02-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2008-12-17
• Last updated: 2011-05-19
• Results posted: 2011-04-13

Locations

34 sites across 1 country: Japan